P3 Health (PIII) Q2 2025 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 14 2025
0mins
Source: NASDAQ.COM
- Author's Perspective: The opinions shared in the article are solely those of the author and do not represent Nasdaq, Inc.
- Data Limitations: The information is based on data available up to October 2023.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PIII?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PIII
Wall Street analysts forecast PIII stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PIII is 14.00 USD with a low forecast of 8.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 2.230
Low
8.00
Averages
14.00
High
20.00
Current: 2.230
Low
8.00
Averages
14.00
High
20.00
About PIII
P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
P3 Health Partners Forms Joint Venture with Commonwealth to Expand Value-Based Care
- Joint Venture Formation: P3 Health Partners and Commonwealth Primary Care ACO have established a Joint Venture Management Services Organization aimed at expanding value-based care support across Arizona, California, Nevada, Oregon, and North Carolina, enhancing service capabilities for primary care physicians.
- Market Expansion: This partnership expands P3's footprint into Maricopa County, Arizona, further solidifying its position in a key growth market, which is expected to drive business growth in the region.
- Operational Efficiency Improvement: The joint venture combines P3's strengths in Medicare Advantage and ACO with Commonwealth's ACO REACH program to create a unified operational platform, thereby enhancing performance and efficiency in healthcare delivery.
- Physician Support Enhancement: The joint venture will strengthen support for independent primary care physicians by sharing operations and best practices, ensuring they can thrive and deliver exceptional care in a value-based environment.
Continue Reading
Projected Target Price for ONEQ Analyst: $104
ETF Performance Analysis: The Fidelity Nasdaq Composite Index ETF (ONEQ) has an implied analyst target price of $103.84, indicating a potential upside of 10.75% from its current trading price of $93.76.
Notable Holdings: Key underlying holdings with significant upside potential include KODIAK ROBOTICS INC (KDK), Red Cat Holdings Inc (RCAT), and P3 Health Partners Inc (PIII), with expected price increases of 96.58%, 62.44%, and 58.15% respectively.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent company and industry developments.
Continue Reading